July 29, 2014 – Toronto, Ontario – Monarch Energy Limited (CSE: CHX) (OTC: MNLIF)(“Monarch” or the “Company“) is pleased to announce that its wholly-owned subsidiary ChroMedX Ltd. has engaged ALine Inc. of Rancho Dominguez, CA as its primary contractor for the development of the Company’s HemoPalm cartridge and analyzer technology. The goal is to complete construction of the prototype cartridge and analyzer to demonstrate functionality of the system by the first quarter of 2015. ALine has expertise in the engineering, prototyping and manufacturing of microfluidic cartridges used in the life sciences and in vitro diagnostic fields. ALine Inc. was founded by current President and CEO, Leanna Levine, Ph.D.
Wayne Maddever, Ph.D. P.Eng, President and CEO of ChroMedX Ltd. said, “The experience and expertise of Leanna and her ALine team make them the perfect partner for the development of the HemoPalm system.”
Leanna Levine, Ph.D., President and CEO of ALine said, “We are excited about the potential for ChroMedX’s technologies and are pleased to be a part of this development.”
The HemoPalm system is comprised of a disposable cartridge and a handheld analyzer. The system measures co-oximetry, blood gases and electrolytes, in a patient’s blood, and the resulting analysis can provide a complete assessment of a patient’s acid-base and oxygenation status at the point of care (POC). The leading competitors in POC testing require a second analyzer to provide CO-oximetry, which is the gold standard for measuring hemoglobin oxygen saturation and total hemoglobin. The ability to provide all the measurements described above in a single central laboratory analyzer has been available since the 1990s. ChroMedX intends to be the first company to provide these measurements in a single handheld analyzer.
In addition to ALine Inc., ChroMedX has engaged additional consultants with expertise in microspectrometry and biosensors to compliment the development team led by James Samsoondar, Ph.D., ChroMedX Chief Scientific Officer.